Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCw5qCUOTByMDFOwI0> MX[yOEBpyqB? MWrpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NYq5[Zl1OjZyOEi3NVE>
POLK WT NUK3SYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fBc2lEPTB;MUGuO-KBkcLz4pEJNU44yqEQvF2= MmXjNlYxOzF2MEC=
POLK KO NXfMR4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NYXYepd2OjZyM{G0NFA>
POLK CD M37XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\3PWRzUUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> NHK2WVQzPjB|MUSwNC=>
RLE/Abca3 MYHGeY5kfGmxbjDBd5NigQ>? MlT6NE41yqEQvF2= MVmxOFTDqGh? M4fpTYlv\HWlZYOgZUBud3KyaH;sc4dq[2GuIHPoZY5o\SCocn;tJIVxcXSqZXzpZYwudGmtZTDtc5JxcG:ub3f5JJRwKGFid3nk[Uwhe3C{ZXHkMY92fCCvb4LwbI9td2e7wrC= M4S2elI2PzZyNUO4
PMCs NF:3UY5HfW6ldHnvckBCe3OjeR?= MnW4NE4y6oDVMtMg{txoN22u NGPBfXczPMLiaB?= NHq1ZWhk[XW|ZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGVicILveIVqdiCuZY\lcEBw\iClb3zsZYdmdi2LwrC= NEf1dXkzPTV7NU[0Ni=>
PMCs NUm2NYVZTnWwY4Tpc44hSXO|YYm= MmfwNE4zyqEQvHevcYw> NX\me5lLOjUkgKO3NuKhcA>? NHXIWldqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? NFrkb5QzPTV7NU[0Ni=>
PMCs M3u3e2Z2dmO2aX;uJGF{e2G7 M3raT|AvOsLizsznM41t MkfiO|IhcA>? NUHNb4N2cW6mdXPld{Bl\WO{ZXHz[ZMhcW5iY4n0c4tmemG2aX6tPEBidmRiRT3jZYRp\XKrbjDwdo91\Wmw MWiyOVU6PTZ2Mh?=
PMCs MVLGeY5kfGmxbjDBd5NigQ>? MXuwMlLDqM7:Zz;tcC=> MkDpNVIwOjRxNEigbC=> NITNd4RqdmO{ZXHz[ZMh[2WubDDtbYdz[XSrb36= NGPVU4MzPTV7NU[0Ni=>
IMR-32 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPKO{426ojUMUKwJOK2\y:vbB?= M3\6blEz6ojUNEigbC=> MYPJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v NHTzbI4zPTV|NkO0OS=>
HT1080 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3OGoyKM7:TR?= MmrPNlQhcMLi NXXQZnZ3dGWjZIOgeI8h[SCJMj;NJIRmdGG7 NIjOR2szPTVzOEm2NS=>
HT1080 MXfGeY5kfGmxbjDBd5NigQ>? NHrJcJUyKM7:TR?= M2LMTlI1KGkEoB?= MnKzbY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= MkL6NlU2OTh7NkG=
HDFn NI[yNWREgXSxdH;4bYNqfHliQYPzZZk> M2\OR|czKGh? NV;FdmoxUUN3ME25MlMyLcLi NUPuSXgyOjV{N{[3PVI>
THP-1 M1yz[mN6fG:2b4jpZ4l1gSCDc4PhfS=> MYS3NkBp NIOweodKSzVyPUSuO|cm MWCyOVI4Pjd7Mh?=
HT-29 MlnwR5l1d3SxeHnjbZR6KEG|c3H5 MY[3NkBp NUnM[lBrUUN3ME2xNU41QSV? MXyyOVI4Pjd7Mh?=
HCT116  Mk[zR5l1d3SxeHnjbZR6KEG|c3H5 MVy3NkBp M131WWlEPTB;MUGuN|Qm NYH6b2pbOjV{N{[3PVI>
A431 NWnq[3dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi1blM2OC1{MECgTXU> NYDvNlFrPDkkgJno M1nX[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{D5fVI2OTBzMkm5
T24 M37Gcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6OVAuOjByIFnV NHKyeHA1QOLCiXi= NXvJXnU4cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MoTmNlUyODF{OUm=
AY-27  MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX21NE0zODBiSWW= M2XENVQ56oDLaB?= M3XyZolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MVqyOVExOTJ7OR?=
A549 NEGwZXhHfW6ldHnvckBCe3OjeR?= MmKwNUDDvWdxbV|CpC=> MoPiNE01QCCq Mn\1bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> Ml;hNlQ6PjN4M{W=
MLE12 NUnTXWxKTnWwY4Tpc44hSXO|YYm= NH3o[pQyKML3Zz;tUOKh NGDzeJIxNTR6IHi= MmnkbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NXHS[HJzOjR7NkO2N|U>
Jurkat NF7NfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nGZlIx6oDLzszt MoPoNlTjiImqwrC= MoD3ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> MmHWNlQ6OTZ6OUO=
HeLa  NEWzd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;nVoRKSzVyPUGwMlLDqM7:TR?= NVTGWXBtOjR5M{KzPVc>
C18-4 NH;OVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMVExOCEQvF2= MnPEbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MnnMNlQ2PzF7OEK=
BMG-1  Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S4c|QxNzhywrFOwIcwdQ>? Mn:yN:KhcA>? NFmxbJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M4fmRlI{QTB4N{K2
A459 NUHtOY1TSXCxcITvd4l{KEG|c3H5 NEm5N5YyOCCvVR?= NVTmUndEPDhiaB?= MWHpcoR2[2W|IHHwc5B1d3Orcx?= M{HmWlI{QTB{N{[2
MOCK MnfZRZBweHSxc3nzJGF{e2G7 M2TEPVExKG2X MVq0PEBp MYLpcoR2[2W|IHHwc5B1d3Orcx?= NI\RfHkzOzlyMke2Oi=>
MMP1 MlzaRZBweHSxc3nzJGF{e2G7 NHHubZcyOCCvVR?= NUnOepRlPDhiaB?= MmfDbY5lfWOnczDhdI9xfG:|aYO= MmrWNlM6ODJ5Nk[=
A549 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQNlAxKM7:TR?= NYTneWlzOjRiaNMg MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NGfWOIMzOzhyNUe5Ny=>
HCT-116 MnezRZBweHSxc3nzJGF{e2G7 MorKN{84NjVxMUWg{txoN22u MXS0PEBp NWCyUIU4emWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? M{HRd|I{PzB6Nk[4
HeLa M{DVWGFxd3C2b4Ppd{BCe3OjeR?= MVSzM|cvPS9zNTFOwIcwdWx? Ml24OFghcA>? M4KxfJJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> MUSyN|cxQDZ4OB?=
HCT116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Gwc|AuOTByIN88[{9udA>? NYfnXFc2PDhiaB?= M3nVVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MnnHNlM2OTh{MEG=
NCM460 M1Hwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMVExOCEQvHevcYw> NVHNWVgyPDhiaB?= NWjUeVV{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Ml\rNlM2OTh{MEG=
NT2  NYewWm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX2NlQhcMLi MUDMSFUxRTRyMPMAjeK2\y:vbB?= Ml7aNlM{QDZ2MkC=
NT2  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[0PEBp MkHBUGQ2OD1zMECgxtVoN22u NXS4eINWOjN|OE[0NlA>
NT2  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NkBp Mn\WUGQ2OD1{MPMAjeK2\y:vbB?= M{nMV|I{Ozh4NEKw
NT2  Mlu2RZBweHSxc3nzJGF{e2G7 NF;5NHA1ODEkgJpCuYcwdWx? M1\mPVI1KGkEoB?= M3vFbIlv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? NYOxRlVzOjN|OE[0NlA>
NTera-2 MV7GeY5kfGmxbjDBd5NigQ>? MW[xNlAh|rypL33s MkTwO|IhcA>? NXH1VHQxe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> M1v3eFIzQDJ3M{W1
NCCIT M2LYZ2Z2dmO2aX;uJGF{e2G7 MXWxNlAh|rypL33s NWHudJdrPzJiaB?= NFHCSXJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> MknSNlI5OjV|NUW=
NTera-2 M1r2SWZ2dmO2aX;uJGF{e2G7 MlLVNVIxKM7:Zz;tcC=> NELNem84OiCq NV\lemU2e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ M2S5eVIzQDJ3M{W1
NCCIT Ml;2SpVv[3Srb36gRZN{[Xl? M4nzPFEzOCEQvHevcYw> MXu3NkBp NX\nPFFOe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NYHSenBLOjJ6MkWzOVU>
NCCIT NWfPXId7TnWwY4Tpc44hSXO|YYm= MWqxNlAh|rypL33s M2H3[VczKGh? MW\zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| NILWboQzOjh{NUO1OS=>
NTera-2 MlrsSpVv[3Srb36gRZN{[Xl? NFfj[GcyOjBizsznM41t M3n6UVczKGh? Ml\rd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> M4jHU|IzQDJ3M{W1
NCCIT MVPGeY5kfGmxbjDBd5NigQ>? M2P3[|EzOCEQvHevcYw> NEfmO204OiCq M2X3VJNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ Mn;ENlI5OjV|NUW=
NTera-2 M{\3UGZ2dmO2aX;uJGF{e2G7 NWjsS3R2OTJyIN88[{9udA>? M{\MelczKGh? NHPLe|h{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz M2PrVFIzQDJ3M{W1
NCCIT NX3tNGl5TnWwY4Tpc44hSXO|YYm= M1HtVFEzOCEQvHevcYw> MkHOO|IhcA>? MoC2d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MmTBNlI5OjV|NUW=
MDA-MB-468 M2\tRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLqbZZWOOLCk{KwNOKh|rypL33M M12zT|I1KGh? NELsOmhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MnfINlI5OTlzOU[=
231-H2N NUfYdWRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DTblDjiJN{MEFCpO69\y:vTB?= NE\sZ|YzPCCq MnXDbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFrxe5gzOjhzOUG5Oi=>
A549  NHPITXpHfW6ldHnvckBCe3OjeR?= Mlq5NlAxNzRyMDFOwG0> MljmdoV{fWy2czDpckBiKGSxc3WtdoV{eG:wc3n2[UBqdmO{ZXHz[UBqdiCUT2O= MkLoNlI4PzN4OUe=
A549  M1zhR2Z2dmO2aX;uJGF{e2G7 M3rRelAuPDByIN88US=> NF3XS|kzNTR6IHi= MXHjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen M4XlW|IzPzd|Nkm3
A549  MkjUSpVv[3Srb36gRZN{[Xl? NXiweHVlOTByIN88UeKh NVrEN|BqOOLCk{S4JIg> M1\JZYNifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M{nTXlIzPzd|Nkm3
A549  MnTDSpVv[3Srb36gRZN{[Xl? MX2xNFAh|ryPwrC= NFnZfGkx6oDVNEigbC=> MXnjZZV{\XNiUFvENUBkdGWjdnHn[S=> M3OyelIzPzd|Nkm3
A549  MXvGeY5kfGmxbjDBd5NigQ>? NU\yPIU4OTByIN88UeKh NYLybXZ[OOLCk{S4JIg> M32wSYNifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? M3rmTVIzPzd|Nkm3
A549  M{PtbWZ2dmO2aX;uJGF{e2G7 NIX4OXQyODBizszNxsA> NGW2NWkx6oDVNEigbC=> Mmm5[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> NVrD[JVsOjJ5N{O2PVc>
MCF-7/Her-18  M3\Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMlQzNTF5MECg{txoN22O NHPiWpEzPCCq NEGyR2xqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmfMNlI3OjF2MES=
MCF-7 MkjVVGRVN1CFSTDUdoVifG2nboS= MVGwMlI2KM7:Zz;tcE4> M1G0UFEuPCCq NYLmWY11e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? M3XFUFIzPTlzMki0
MDA-MB-231 M4f4[nBFXC:SQ1mgWJJm[XSvZX70 MnTENE4zPSEQvHevcYwv NHTBUmQyNTRiaB?= NHfpPFB{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 M1;jSFIzPTlzMki0
MDA-MB-235  MUPQSHQwWEOLIGTy[YF1dWWwdB?= NWHaTW1yOC5{NTFOwIcwdWxw NWLKbYFROS12IHi= Mm\hd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> NXnHZ4RGOjJ3OUGyPFQ>
MCF-7 NUfPdo93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rUWFAuOiEQvHevcYwv Mon3NlQwPDhiaB?= NVL3cI5bTUN3ME2xMlIh|rypL33M M17mbFIzPTlzMki0
NCCIT  MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrVfJMzOOLCk{G0NOKh|rypL33s MVG3NkBp NGPPeIRNTDVyPUGyNOKh|rypL33sxsA> M1T1NFIzPTZ{MU[w
NCCIT  Moe4SpVv[3Srb36gRZN{[Xl? Mo\iO|IhcA>? NHvMNpp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> MYeyNlU3OjF4MB?=
NCCIT  MX7GeY5kfGmxbjDBd5NigQ>? NF;Ze2k4OiCq NILsN2p{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> MkX3NlI2PjJzNkC=
NCCIT  NGfFPXVHfW6ldHnvckBCe3OjeR?= M1fMNVczKGh? NX7SNWNUe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT25JIFkfGm4aYT5xsA> M{fCS|IzPTZ{MU[w
NCCIT  MX7GeY5kfGmxbjDBd5NigQ>? NFXmR5c4OiCq NILYVlR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= MYKyNlU3OjF4MB?=
NCCIT  NIn2U2RHfW6ldHnvckBCe3OjeR?= MVm3NkBp MUfzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? NY\GU2ZLOjJ3NkKxOlA>
NCCIT  NUnKfpNXTnWwY4Tpc44hSXO|YYm= NH;6dWo4OiCq NWS0RmQ2e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEO7dD3jJIxmfmWu MkXDNlI2PjJzNkC=
HeLa MofESpVv[3Srb36gRZN{[Xl? MVOzNE84OCEQvHevcYw> NHrZcVczPMLiaB?= NX3mRYx6cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? NGjEXoYzOjR6N{mzOy=>
MCF-7  NFXvT|NHfW6ldHnvckBCe3OjeR?= NV\SRXFTOzBxN{Cg{txoN22u M3zpdFI1yqCq NV7NN212cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? M4G5VlIzPDh5OUO3
HeLa MlzoR5l1d3SxeHnjbZR6KEG|c3H5 MnXEN|AwPzBizsznM41t M1rV[VI1yqCq NGmxR4ZqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= MlzpNlI1QDd7M{e=
MCF-7  NILBclJEgXSxdH;4bYNqfHliQYPzZZk> NHLsNYc{OC95MDFOwIcwdWx? NIrXVW0zPMLiaB?= M2DWT4lv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= MkjsNlI1QDd7M{e=
NT2 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP4[GhVOTByLU[wNOKh|rypL33s NV7McY1NOjRiaB?= NF:xUGFKSzVyPUSwNEDDvWdxbXy= NYPNdpo3OjJ2Nkm5OVI>
NT2 M3fwbWZ2dmO2aX;uJGF{e2G7 M{PGflQxOMLizsznM41t NGrYdXYzPCCq M2qxPJNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? NUHXbVdHOjJ2Nkm5OVI>
NT2 MYHGeY5kfGmxbjDBd5NigQ>? MXy0NFDDqM7:Zz;tcC=> NFT6cpAzPCCq MV3zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NUXjWWdXOjJ2Nkm5OVI>
NT2 NIjWfplHfW6ldHnvckBCe3OjeR?= MmD6OFAxyqEQvHevcYw> NFftOXIzPCCq M3zuS5Nq\26rZnnjZY51dHliZHXjdoVie2W|IFLjcE0zKGyndnXs M4DZZlIzPDZ7OUWy
CHO MlzKSpVv[3Srb36gRZN{[Xl? M{SwOVIvPcLizsznM41t MX[xPEBpNzZiZB?= MULpcoR2[2W|wrDw[ZJ{cXO2ZX7j[UBw\iClaILvcY9{d22nIHThcYFo\Q>? NGPPfFYzOjJ|MEG5OS=>
Jurkat MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L3R|AuOTBywrFOwIcwdWx? MlzENlQhcA>? MoLXZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> NFvrXFEzOjJ{M{OzNi=>
Jurkat MnXSSpVv[3Srb36gRZN{[Xl? NFy4Rpk{OMLizsznM41t M3ryV|I1KGh? NILqPZlqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIHP5Z4xqdnNiREOsJGEh[W6mIFKx MmizNlIzOjN|M{K=
Jurkat M{HSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;MXVA5OC1zMEFCpO69\y:vbB?= M4S0OlI1KGh? NWPISmNqcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigZY4hUUN3MDD2ZYx2\SCxZjCxNFDPxGdxbVy= M1HTflIzOjJ|M{Oy
Jurkat M1zHcWZ2dmO2aX;uJGF{e2G7 M{jocVMxyqEQvHevcYw> MWiyOEBp MmW5bY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? MlXnNlIzOjN|M{K=
U2OS EGFPnls M1L1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XielAuOsLizsznM41t Mk\0NlQhcA>? M1ziOolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MWOyNVgyOTByNx?=
U2OS KuEnls MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFizXGExNTMEoN88[{9udA>? MYGyOEBp MWfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXOyNVgyOTByNx?=
MCF-7 NXPqUFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTXNE01ODBizszN MlH6O|IhcA>? MnH2UGM2OD1zNUGuPOKh|ryP M3n6fVIyPzB|Mkmx
MCF-7/Adr  Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zGeVAuPDByIN88US=> MkDtO|IhcA>? MXnMR|UxRTV6LkZCpO69VcLi M{\x[FIyPzB|Mkmx
WI-38 M2nGd2Z2dmO2aX;uJGF{e2G7 M{GxRVAwPDBxOEFihKnPxGdxbX|CpC=> MkHHN{Bp NYrqdIU5cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NIjyfnIzOTV7OU[xNi=>
hBMSC M4PWdmZ2dmO2aX;uJGF{e2G7 Mm\INE81OC96MPMAje69\y:vbNMg NWTzVWZKOyCq MVnpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg Mm\mNlE2QTl4MUK=
NCI-H23 NF;2SYhHfW6ldHnvckBCe3OjeR?= NFXTco8xNzRyL{iw5qCK|rypL33sxsA> M13zWFMhcA>? M1PLSIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NH;WVI4zOTV7OU[xNi=>
A-549 M4jxT2Z2dmO2aX;uJGF{e2G7 NV\zSJlVOC92MD:4NQKBkc7:Zz;tcOKh NEPpNW8{KGh? MWPpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg Mn;SNlE2QTl4MUK=
PBL  MVvGeY5kfGmxbjDBd5NigQ>? MnrENE81OC96MPMAje69\y:vbNMg NFnlWJg{KGh? MV7pcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg Mm\mNlE2QTl4MUK=
pol β −/− MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HrblAvOjVvMkCwxsDPxGdxbXy= NVL0VpB4OjUEoHi= NVmxSIty\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MVyyNVI2OTl2NB?=
pol β +/+ M1P1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nxT|AvOjVvMkCwxsDPxGdxbXy= NIPLWYMzPMLiaB?= NXrOZW91\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NYrkVFRUOjF{NUG5OFQ>
pol β −/− Mk\mSpVv[3Srb36gRZN{[Xl? M1rmRVAuOi53IN88[{9udA>? M1;kOlIhcA>? M{P5T4NifXOnczDEUmEh\GGvYXfl MlXaNlEzPTF7NES=
pol β +/+ MnXISpVv[3Srb36gRZN{[Xl? M3jJZ|AuOi53IN88[{9udA>? MWKyJIg> NGXoZ25k[XW|ZYOgSG5CKGSjbXHn[S=> NUjXflhWOjF{NUG5OFQ>
pol β −/− M1\NS2Z2dmO2aX;uJGF{e2G7 NGPGSncxNTVizsznM41t MmryOFghcA>? NVrrfYNF[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NX3DVVk6OjF{NUG5OFQ>
pol β +/+ MknWSpVv[3Srb36gRZN{[Xl? NW[wd|V5OC13IN88[{9udA>? MVu0PEBp M3qyXINifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NV3XZ2NvOjF{NUG5OFQ>
TK6  M1fqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTIRotlOjVvMUWwJO69\y:vbB?= M4jSfVk3KGh? Mmn1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MX:yNVA5OTR6Nx?=
TK6  sLUC+Apn1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXnNlUuOTVyIN88[{9udA>? NWn5UXFqQTZiaB?= MUfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NHLnNXgzOTB6MUS4Oy=>
TK6 sAPE1+Apn1 M1PKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzXNlUuOTVyIN88[{9udA>? NF;GTYE6PiCq MYrzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? NGr5fZQzOTB6MUS4Oy=>
HCT116 M4HyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknzNlUuOTVyIN88[{9udA>? NXnmdHlFQTZiaB?= MV;pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWC5TmtiOjFyOEG0PFc>
HCT116 sLUC+Apn1 NWXKUW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITvb2YzPS1zNUCg{txoN22u NVO1O5RrQTZiaB?= NIDkfGlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MX2yNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 NEfVSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDXd2U5OjVvMUWwJO69\y:vbB?= NFzrdGI6PiCq MnjFd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 NVvTblBLOjFyOEG0PFc>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID